Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study

BACKGROUND: Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have shown promising antitumor activity against a range of advanced cancers. However, evidence is lacking as to whether this combination therapy could benefit thymic epithelial tumors (TETs). We aimed to explore the...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Jing, Si, Jinfei, Hao, Yue, Wei, Jingwen, Wang, Wenxian, Guan, Yelan, Xu, Chunwei, Song, Zhengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080305/
https://www.ncbi.nlm.nih.gov/pubmed/37033336
http://dx.doi.org/10.21037/tcr-22-2192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080305/
https://www.ncbi.nlm.nih.gov/pubmed/37033336
http://dx.doi.org/10.21037/tcr-22-2192

Ejemplares similares